Shares are to be offered to private and institutional investors in Germany and Luxembourg through a public offering. Outside of these countries, the plan is to offer the shares to institutional investors via private placements. In the U. Securities Act of The planned IPO is the logical next step. In these areas, it focuses on market segments and regions with sustained high growth potential.
|Published (Last):||13 April 2013|
|PDF File Size:||13.60 Mb|
|ePub File Size:||9.49 Mb|
|Price:||Free* [*Free Regsitration Required]|
Shares are to be offered to private and institutional investors in Germany and Luxembourg through a public offering. Outside of these countries, the plan is to offer the shares to institutional investors via private placements.
In the U. Securities Act of The planned IPO is the logical next step. In these areas, it focuses on market segments and regions with sustained high growth potential.
In , Evonik generated more than 80 percent of its chemicals sales in fields in which it ranks among the market leaders.
The company derives benefits from its integrated technology platforms, which undergo continuous development. These platforms generate growth and cost benefits and represent significant market entry barriers for competitors. Furthermore, Evonik has a balanced spectrum of business activities and end-markets and a balanced regional presence. Further strengths are proximity to customers and market-oriented research and development. It continued to build on these very good results in the first quarter of After adjustment for the carbon black business, which was divested in , Evonik expects that full-year sales in will be slightly higher than in and that the operating results will probably be in line with or slightly above the excellent level reported for Based on the present timeline, publication of the securities prospectus and the start of trading in the shares is expected to take place before the summer break.
Morgan are mandated. Disclaimer These materials must not be published, distributed or transmitted in the United States, Canada, Australia or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities the "Shares" of Evonik Industries AG the "Company" in the United States, Germany or any other jurisdiction.
The Shares of the Company may not be offered or sold in the United States absent registration on exemption from registration under the U. Securities Act of , as amended the "Securities Act". The Shares of the Company have not been, and will not be, registered under the Securities Act.
This publication constitutes neither an offer to sell nor a solicitation to buy securities. The offer will be made solely by means of, and on the basis of, a securities prospectus which is to be published. An investment decision regarding the publicly offered securities of Evonik Industries AG should only be made on the basis of the securities prospectus.
In the United Kingdom, this document is only been distributed to and is only directed at persons who i are investment professionals falling within Article 19 5 of the Financial Services and Market Act Financial Promotion Order as amended the "Order" or ii are persons falling within Article 49 2 a to d of the Order high net worth companies, unincorporated associations, etc.
This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
In so far as forecasts or expectations are expressed in this investor relations news or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties.
Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
EVONIK IPO PROSPECTUS PDF
Faumi Prior to the Acquisition, the Company had no operations. Further strengths are proximity to customers and market-oriented research and development. When we file a patent application, it is usually filed pdospectus all countries with active competition, where we have existing customers. The redemption notice was given at least 30 days in advance of the redemption date and is irrevocable, subject to the closing of this offering and evnoik Refinancing having occurred. We obtain a considerable portion of our raw materials and energy from selected key suppliers. In periods with significant market turmoil and tightened credit availability, we expect to experience difficulty in collecting accounts receivable, pricing pressure and reduced global business activity.
Tinyu PDF Me
Insufficient protection of intellectual property may limit our ability to make prospectys of technological advantages or result in a reduction of future profits. The market status window is an indication regarding the current technical availability of the trading system. We have eovnik capacity in South Korea and will be using the additional volumes of this unit to address the markets in South Korea and the larger Asia-Pacific region, which should help expand our market share in that region. Carbon black product properties are influenced by the choice of production technology and operating parameters. Filed Pursuant to Rule b 4 Registration No. As this region grows, we will be prepared to add capacity to this facility.